BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 2460958)

  • 1. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
    Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
    Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adult onset nesidioblastosis: response of glucose, insulin, and secondary peptides to therapy with Sandostatin.
    Mozell EJ; Woltering EA; O'Dorisio TM; Phillipson BE; Fletcher J; Fletcher WS; Howe B; Hill D; Rhea D
    Am J Gastroenterol; 1990 Feb; 85(2):181-8. PubMed ID: 2405644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome.
    Mozell E; Woltering EA; O'Dorisio TM; Fletcher WS; Sinclair AJ; Hill D
    Surg Gynecol Obstet; 1990 Jun; 170(6):476-84. PubMed ID: 2188384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
    Williams G; Anderson JV; Williams SJ; Bloom SR
    Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas.
    Ellison EC; O'Dorisio TM; Sparks J; Mekhjian HS; Fromkes JJ; Woltering EA; Carey LC
    Surgery; 1986 Aug; 100(2):437-44. PubMed ID: 2426819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome.
    Altimari AF; Bhoopalam N; O'Dorsio T; Lange CL; Sandberg L; Prinz RA
    Surgery; 1986 Dec; 100(6):989-96. PubMed ID: 2878500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors.
    Wynick D; Williams SJ; Bloom SR
    N Engl J Med; 1988 Sep; 319(10):605-7. PubMed ID: 2842676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical experience with functioning pancreatic neuroendocrine tumors.
    Matthews BD; Smith TI; Kercher KW; Holder WD; Heniford BT
    Am Surg; 2002 Aug; 68(8):660-5; discussion 665-6. PubMed ID: 12206598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
    Vinik AI; Tsai S; Moattari AR; Cheung P
    Surgery; 1988 Nov; 104(5):834-42. PubMed ID: 2903562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
    Arnold R; Neuhaus C; Trautmann ME
    Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
    [No Abstract]   [Full Text] [Related]  

  • 11. Somatostatin analog: effects on hypergastrinemia and hypercalcitoninemia.
    Geelhoed GW; Bass BL; Mertz SL; Becker KL
    Surgery; 1986 Dec; 100(6):962-70. PubMed ID: 2431492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors.
    Maton PN; Gardner JD; Jensen RT
    Dig Dis Sci; 1989 Mar; 34(3 Suppl):28S-39S. PubMed ID: 2537716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunoassay in diagnosis, localization and treatment of endocrine tumours in gut and pancreas.
    Rehfeld JF
    Scand J Gastroenterol Suppl; 1979; 53():33-8. PubMed ID: 225784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995).
    Kvols LK; Buck M; Moertel CG; Schutt AJ; Rubin J; O'Connell MJ; Hahn RG
    Ann Intern Med; 1987 Aug; 107(2):162-8. PubMed ID: 2886085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative use of long-acting somatostatin analog (SMS 201-995) in patients with endocrine tumors of the gastroenteropancreatic axis.
    Tsai ST; Eckhauser FE; Thompson NW; Strodel WE; Vinik AI
    Surgery; 1986 Oct; 100(4):788-95. PubMed ID: 2876529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Peptide-producing tumors in the pancreas and gastrointestinal tract: syndrome, survey, therapy].
    Hemmingson A; Johansson H; Lindgren PG; Lundqvist G; Lörelius LE; Wide L; Wilander E; Oberg K
    Lakartidningen; 1984 Aug; 81(35):3015-21. PubMed ID: 6147450
    [No Abstract]   [Full Text] [Related]  

  • 17. Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995.
    Glaser B; Rösler A; Halperin Y
    Isr J Med Sci; 1990 Jan; 26(1):16-9. PubMed ID: 2155884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple hormone elevations in Zollinger-Ellison syndrome. Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome.
    Chiang HC; O'Dorisio TM; Huang SC; Maton PN; Gardner JD; Jensen RT
    Gastroenterology; 1990 Dec; 99(6):1565-75. PubMed ID: 2227272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Somatostatin analogue in the treatment of neuroendocrine gut tumors].
    Ben Yosef R; Glaser B; Catane R
    Harefuah; 1990 Jul; 119(1-2):15-8. PubMed ID: 2172125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses.
    Moattari AR; Cho K; Vinik AI
    Surgery; 1990 Sep; 108(3):581-7. PubMed ID: 2168587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.